US Equities Futures Crawl into Black, Bucking Broader Trend

U.S. stock futures managed to edge into positive territory on Monday, trading flat to higher closer to the open, even as overseas markets were broadly lower and weak crude oil prices weighed on sentiment.

The Federal Open Market Committee starts its two-day meeting Tuesday, culminating in an announcement on Wednesday at 2 p.m. E.T.

Recently, West Texas Intermediate crude for delivery in January was down over 2% at $34.81. Brent Crude was down over 3% at $36.53.

In equities, Newell Rubbermaid ( NWL ) fell over 8% in recent pre-market trade after agreeing to acquire Jarden Corporation ( JAH ) for $13.2 billion. JAH was up over 2%. The deal will create a consumer goods company with about $16 billion in yearly sales.


-Dow Jones Industrial up 0.08%

-S&P 500 futures up 0.17%

-Nasdaq 100 futures up 0.04%

-Nasdaq 100 pre-market indicator down 0.05%


Nikkei down 1.80%

Hang Seng down 0.72%

Shanghai Composite up 2.51%

FTSE-100 up 0.31%

DAX-30 down 0.79%


(+/-) Large cap tech: mixed

(-) Chip stocks: unchanged to lower

(+/-) Software stocks: mixed

(-) Hardware stocks: unchanged to lower

(+/-) Internet stocks: mixed

(+/-) Drug stocks: mixed

(-) Financial stocks: unchanged to lower

(-) Retail stocks: unchanged to lower

(+/-) Industrial stocks: mixed

(+/-) Airlines: mixed

(-) Autos: unchanged to lower


(+) MU (+3.3%) Strikes $3.2 billion deal to buy remaining stake in Inotera joint venture

(+) SPIL (+17.5%) Gets $8.25/ADS offer from ASX (-3.7%)

(+) KTOV (+16.3%) Gains ahead of Tuesday presentation on drug to treat high blood pressure and osteoarthritis pain

(+) AKBA (+12.8%) To get milestone payments under deal with Mitsubishi Tanabe Pharma to develop chronic kidney disease anemia drug

(+) CTIC (+2.7%) Gets $10 million milestone payment from TEVA for anti-cancer agent Trisenox

(+) TSL (+7.9%) Gets $11.6/ADS go-private offer from chairman

(+) BLRX (+3.1%) Files to start phase 2 trial of leukemia drug

(+) IMNP (+15.5%) Reports positive data on bi-specified antibody

(+) MNOV (+6.3%) Reports positive interim data on Ibudilast for amyothrophic lateral sclerosis


(-) AZN (-6.3%) Confirms talks to acquire privately-held Acerta Pharma

(-) GBSN (-25.0%) Extends Friday's losses after 1-for-60 reverse stock split

(-) PSTI (-9.2%) UTHR scraps licensing agreement for pulmonary arterial hypertension drug

(-) ECA (-4.9%) 2016 capital budget seen $600 million lower than 2015

(-) ATRA (-37.4%) Suspends development of end stage renal disease drug as trial doesn't meet endpoint

(-) BIND (-11.3%) Won't advance KRAS mutant NSCLC arm to second stage

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 All rights reserved. Unauthorized reproduction is strictly prohibited.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos